광견병 백신 시장 : 제품 유형별, 유형별, 용도별, 유통 채널별, 세계 예측(2024-2032)

Rabies Vaccine Market size is projected to record 4.5% CAGR from 2024 to 2032, driven by advancements in vaccine technologies and the expansion of healthcare infrastructure. Ongoing developments in vaccine research are leading to more effective and easier-to-administer vaccines for enhancing protection against rabies.

The surging focus on healthcare infrastructure is improving vaccine distribution and accessibility, especially in regions where rabies is more prevalent. Moreover, the growing efforts on refining vaccine formulations and increasing global availability will drive the market growth. For instance, in August 2022, Cadila Pharma launched the world's first novel 3-dose vaccine against rabies to enhance rabies prevention with a streamlined dosing schedule for marking a significant advancement in the fight against this deadly disease.

The overall market is segregated into product type, type, application, distribution channel, and region.

In terms of type, the veterinary segment in the rabies vaccine market may experience significant growth by 2032, propelled by increasing adoption to improve animal health and enhance disease control. Ongoing advancements are making way for more effective and longer-lasting vaccines for pets and livestock to provide better protection against rabies. Improved veterinary vaccines are preventing rabies transmission from animals to humans as well as in controlling outbreaks.

By distribution channel, the rabies vaccine industry value from the online pharmacy segment is projected to rise from 2024 to 2032, driven by increasing consumer demand for making rabies vaccine more accessible to pet owners and veterinarians. This shift is enabling easier procurement of vaccines for immediate use and for managing rabies prevention protocols. Online platforms are also working on streamlining the ordering process and ensuring proper storage and handling of the vaccines during shipping.

Regionally, the Asia Pacific rabies vaccine market size is projected to exhibit robust growth between 2024 and 2032, fueled by the rising incidences of rabies and the increasing awareness and prevention programs. Health organizations and governments are promoting rabies vaccination and enhancing public knowledge about prevention strategies. Moreover, enhanced preventive measures and vaccination coverage are controlling rabies outbreaks and reducing incidence rates, adding to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of rabies
    • 3.2.1.2 Technological advancements in vaccine production
    • 3.2.1.3 Growing pet population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of vaccines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Baby hamster kidney (BHK)
• 5.3 Purified chick embryo cell rabies vaccine
• 5.4 Vero cell rabies vaccine
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Human
• 6.3 Veterinary

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pre exposure prophylaxis
• 7.3 Post exposure prophylaxis

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bavarian Nordic A/S
• 10.2 Bharat Biotech International Limited
• 10.3 Bio-Manguinhos/Fiocruz
• 10.4 Cadila Pharmaceuticals
• 10.5 China National Biotec Group Co.
• 10.6 Elanco Animal Health Incorporated
• 10.7 GSK plc.
• 10.8 Indian Immunologicals Ltd.
• 10.9 Liaoning Chengda Biological
• 10.10 Merck & Co., Inc.
• 10.11 Novartis AG
• 10.12 Sanofi SA
• 10.13 Serum Institute of India Pvt. Ltd
• 10.14 Virbac
• 10.15 Zoetis Inc.